Summit Therapeutics Inc. · NASDAQ:SMMT
Summit Therapeutics — Fact Sheet (January 2023)
4 slides from Summit Therapeutics's fact sheet, January 2023
Slide 1: Ivonescimab (SMT112): Potential First-in-Class PD-1/VEGF Bispecific Antibody
Ivonescimab (SMT112) Potential First-in-Class PD-1/VEGF Bispecific Antibody Ivonescimab is an investigational therapy that is not approved by any regulatory authority. It is currently being investigated in Phase III clinical studies.
Slide 2: Ivonescimab (SMT112) PD-1/VEGF Bispecific Antibody
IVONESCIMAB (SMT112) PD-1/VEGF Bispecific Antibody Ivonescimab, known as AK112 in China and non-Summit territories, and also as SMT112 in the United States, Canada, Europe, and Japan (Summit License Territories), is a novel, potential first-in-class bispecific antibody combining the effects of immun
Slide 3: Ivonescimab engineered to bring two established oncology targets together
IVONESCIMAB (SMT112) PD-1/VEGF Bispecific Antibody Ivonescimab was engineered to bring two well established oncology targeted therapies together.
Slide 4: Ivonescimab Has Received Breakthrough Therapy Designation in China
IVONESCIMAB (SMT112) PD-1/VEGF Bispecific Antibody Ivonescimab Has Received Breakthrough Therapy Designation Status in China1 from the National Medical Products Administration (NMPA) for three indications: combination therapy with chemotherapy for non-small cell lung cancer (NSCLC) patients who have
Summit Therapeutics — Fact Sheet (January 2023) on 6ix